EE03683B1 - Asendatud kinoksaliin-2,3-dioonide alküülamiinderivaadid kui glutamaatretseptori antagonistid - Google Patents

Asendatud kinoksaliin-2,3-dioonide alküülamiinderivaadid kui glutamaatretseptori antagonistid

Info

Publication number: EE03683B1
Authority: EE; Estonia
Prior art keywords: substituted quinoxaline; dione; receptor antagonists; glutamate receptor; alkylamine derivatives
Prior art date: 1995-06-07

Application number

EE9700338A

Other languages

English (en)

Estonian (et)

Other versions

EE9700338A (et

Inventor

Edward Kornberg Brian

Shridhar Nikam Sham

Francis Rafferty Michael

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-05-13

Publication date

2002-04-15

1996-05-13 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

1998-06-15 Publication of EE9700338A publication Critical patent/EE9700338A/xx

2002-04-15 Publication of EE03683B1 publication Critical patent/EE03683B1/xx

Links

SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical class C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 title abstract 2
150000003973 alkyl amines Chemical class 0.000 title 1
239000003825 glutamate receptor antagonist Substances 0.000 title 1
206010008118 cerebral infarction Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002660 Anoxia Diseases 0.000 abstract 1
241000976983 Anoxia Species 0.000 abstract 1
201000006474 Brain Ischemia Diseases 0.000 abstract 1
206010008120 Cerebral ischaemia Diseases 0.000 abstract 1
206010014498 Embolic stroke Diseases 0.000 abstract 1
229940122459 Glutamate antagonist Drugs 0.000 abstract 1
208000010496 Heart Arrest Diseases 0.000 abstract 1
208000016988 Hemorrhagic Stroke Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
208000013016 Hypoglycemia Diseases 0.000 abstract 1
206010021143 Hypoxia Diseases 0.000 abstract 1
206010028923 Neonatal asphyxia Diseases 0.000 abstract 1
208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
239000003194 amino acid receptor blocking agent Substances 0.000 abstract 1
230000007953 anoxia Effects 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
230000002218 hypoglycaemic effect Effects 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
208000020658 intracerebral hemorrhage Diseases 0.000 abstract 1
208000001286 intracranial vasospasm Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000004090 neuroprotective agent Substances 0.000 abstract 1
208000033300 perinatal asphyxia Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000005809 status epilepticus Diseases 0.000 abstract 1
230000009424 thromboembolic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Obesity (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

EE9700338A 1995-06-07 1996-05-13 Asendatud kinoksaliin-2,3-dioonide alküülamiinderivaadid kui glutamaatretseptori antagonistid EE03683B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/474,876 US5654303A (en)	1995-06-07	1995-06-07	Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
PCT/US1996/006818 WO1996040651A1 (en)	1995-06-07	1996-05-13	Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists

Publications (2)

Publication Number	Publication Date
EE9700338A EE9700338A (et)	1998-06-15
EE03683B1 true EE03683B1 (et)	2002-04-15

Family

ID=23885301

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EE9700338A EE03683B1 (et)	1995-06-07	1996-05-13	Asendatud kinoksaliin-2,3-dioonide alküülamiinderivaadid kui glutamaatretseptori antagonistid

Country Status (24)

Country	Link
US (1)	US5654303A (de)
EP (1)	EP0837854B1 (de)
JP (1)	JPH11506725A (de)
KR (1)	KR19990022481A (de)
AT (1)	ATE229512T1 (de)
AU (1)	AU716156B2 (de)
BG (1)	BG63462B1 (de)
CA (1)	CA2219755A1 (de)
CZ (1)	CZ290899B6 (de)
DE (1)	DE69625361T2 (de)
DK (1)	DK0837854T3 (de)
EA (1)	EA000762B1 (de)
EE (1)	EE03683B1 (de)
ES (1)	ES2187650T3 (de)
HU (2)	HUP9900883A3 (de)
MX (1)	MX9708431A (de)
NO (1)	NO309088B1 (de)
NZ (1)	NZ308318A (de)
PL (1)	PL186764B1 (de)
PT (1)	PT837854E (de)
SK (1)	SK283181B6 (de)
UA (1)	UA48183C2 (de)
WO (1)	WO1996040651A1 (de)
ZA (1)	ZA964760B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0784054T3 (da) *	1994-09-27	2002-03-25	Yamanouchi Pharma Co Ltd	1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
US6191134B1 (en)	1996-06-05	2001-02-20	Warner-Lambert Company	Amide derivatives of substituted quinoxaline 2, 3-diones as glutamate receptor antagonists
US6015800A (en) *	1997-09-03	2000-01-18	Warner-Lambert Company	Substituted quinoxaline-2-ones as glutamate receptor antagonists
IL125950A0 (en) *	1997-09-05	1999-04-11	Pfizer Prod Inc	Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
US6391922B1 (en)	1998-01-13	2002-05-21	Synchroneuron, Llc	Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US20040152694A1 (en) *	2003-02-04	2004-08-05	Istvan Kurucz	Methods and compositions for treating inflammatory disorders of the airways
EP2338492A1 (de)	2009-12-24	2011-06-29	Universidad del Pais Vasco	Verfahren und Zusammensetzung zur Behandlung von Alzheimer
CN110642798B (zh) *	2019-11-10	2020-07-24	湖南科技学院	一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法
KR20260002803A (ko) *	2023-05-02	2026-01-06	지위, 엘엘씨	치료적 사용을 위한 암브록솔의 변형된 형태

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3992378A (en) *	1973-12-26	1976-11-16	Eli Lilly And Company	Fluoralkyl quinoxadinediones
JPH05117276A (ja) *	1991-10-23	1993-05-14	Sumitomo Pharmaceut Co Ltd	新規な３環性キノキサリンジオン誘導体
JPH06228112A (ja) *	1993-02-05	1994-08-16	Yamanouchi Pharmaceut Co Ltd	（１ｈ，４ｈ）キノキサリン誘導体
TW260660B (de) *	1993-04-22	1995-10-21	Sumitomo Pharma
WO1994026747A1 (en) *	1993-05-13	1994-11-24	Neurosearch A/S	Ampa antagonists and a method of treatment therewith
US5631373A (en) *	1993-11-05	1997-05-20	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon	Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

1995
- 1995-06-07 US US08/474,876 patent/US5654303A/en not_active Expired - Fee Related
1996
- 1996-05-13 EP EP96914617A patent/EP0837854B1/de not_active Expired - Lifetime
- 1996-05-13 AT AT96914617T patent/ATE229512T1/de not_active IP Right Cessation
- 1996-05-13 NZ NZ308318A patent/NZ308318A/en unknown
- 1996-05-13 CZ CZ19973872A patent/CZ290899B6/cs not_active IP Right Cessation
- 1996-05-13 JP JP9500558A patent/JPH11506725A/ja not_active Ceased
- 1996-05-13 EA EA199800008A patent/EA000762B1/ru not_active IP Right Cessation
- 1996-05-13 HU HU9900883A patent/HUP9900883A3/hu unknown
- 1996-05-13 SK SK1690-97A patent/SK283181B6/sk unknown
- 1996-05-13 KR KR1019970708962A patent/KR19990022481A/ko not_active Ceased
- 1996-05-13 CA CA002219755A patent/CA2219755A1/en not_active Abandoned
- 1996-05-13 WO PCT/US1996/006818 patent/WO1996040651A1/en not_active Ceased
- 1996-05-13 UA UA98010046A patent/UA48183C2/uk unknown
- 1996-05-13 HU HU9802568A patent/HUP9802568A3/hu unknown
- 1996-05-13 EE EE9700338A patent/EE03683B1/xx not_active IP Right Cessation
- 1996-05-13 ES ES96914617T patent/ES2187650T3/es not_active Expired - Lifetime
- 1996-05-13 DE DE69625361T patent/DE69625361T2/de not_active Expired - Fee Related
- 1996-05-13 MX MX9708431A patent/MX9708431A/es not_active IP Right Cessation
- 1996-05-13 PL PL96323824A patent/PL186764B1/pl unknown
- 1996-05-13 PT PT96914617T patent/PT837854E/pt unknown
- 1996-05-13 AU AU57920/96A patent/AU716156B2/en not_active Ceased
- 1996-05-13 DK DK96914617T patent/DK0837854T3/da active
- 1996-06-06 ZA ZA964760A patent/ZA964760B/xx unknown
1997
- 1997-11-27 BG BG102079A patent/BG63462B1/bg unknown
- 1997-12-05 NO NO975703A patent/NO309088B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO309088B1 (no)	2000-12-11
PL323824A1 (en)	1998-04-27
NZ308318A (en)	2001-04-27
AU716156B2 (en)	2000-02-17
US5654303A (en)	1997-08-05
CA2219755A1 (en)	1996-12-19
JPH11506725A (ja)	1999-06-15
DK0837854T3 (da)	2003-03-31
BG63462B1 (bg)	2002-02-28
SK169097A3 (en)	1998-07-08
UA48183C2 (uk)	2002-08-15
NO975703D0 (no)	1997-12-05
HUP9900883A2 (hu)	1999-09-28
SK283181B6 (sk)	2003-03-04
WO1996040651A1 (en)	1996-12-19
BG102079A (en)	1998-11-30
EA000762B1 (ru)	2000-04-24
NO975703L (no)	1997-12-05
PT837854E (pt)	2003-03-31
CZ387297A3 (cs)	1998-05-13
EP0837854B1 (de)	2002-12-11
ATE229512T1 (de)	2002-12-15
EE9700338A (et)	1998-06-15
AU5792096A (en)	1996-12-30
PL186764B1 (pl)	2004-02-27
DE69625361D1 (de)	2003-01-23
EP0837854A1 (de)	1998-04-29
HUP9900883A3 (en)	2001-02-28
HUP9802568A3 (en)	2000-01-28
ZA964760B (en)	1997-01-08
KR19990022481A (ko)	1999-03-25
ES2187650T3 (es)	2003-06-16
EA199800008A1 (ru)	1998-06-25
MX9708431A (es)	1998-02-28
CZ290899B6 (cs)	2002-11-13
DE69625361T2 (de)	2003-04-17
HUP9802568A2 (hu)	1999-03-29

Legal Events

Date	Code	Title	Description
2003-02-17	KB4A	Valid patent at the end of a year	Effective date: 20021231
2004-02-16	KB4A	Valid patent at the end of a year	Effective date: 20031231
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2006-02-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20050513

Publication	Publication Date	Title
EE03352B1 (et)	2001-02-15	Asendatud kinoksaliin-2,3-diooni derivaatide aminohappe derivaadid kui glutamaatretseptori antagonistid
RU94046067A (ru)	1996-09-27	Замещенные 1,2,3,4-тетрагидроизохинолины, промежуточные продукты, фармкомпозиция и способ лечения
EE03683B1 (et)	2002-04-15	Asendatud kinoksaliin-2,3-dioonide alküülamiinderivaadid kui glutamaatretseptori antagonistid
GT200200084A (es)	2003-09-12	Sales tartrato de 5, 8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno ycomposicionesfarmaceuticas de las mismas
MX9805032A (es)	1998-11-30	Analogos de piperidina 4-sustituida y su uso como antagonistas del receptor de d-asparatato de n-metilo, selectivos para el subtipo.
AP2002002664A0 (en)	2002-12-31	Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
MY120976A (en)	2005-12-30	2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
AP2002002697A0 (en)	2002-12-31	Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
ES2151168T3 (es)	2000-12-16	N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
MX9708563A (es)	1997-12-31	Derivados aminociclicos de quinoxalina 2, 3-diones substituidos como antagonistas del receptor de glutamato.
AU2001263130A1 (en)	2001-12-17	Bicyclic cyclohexylamines and their use as nmda receptor antagonists
ATE267600T1 (de)	2004-06-15	Mikroemulsionen zur transdermalen verabreichung von apomorphin für die behandlung von morbus parkinson
FI960051A0 (fi)	1996-01-05	Difluoristatonianalogeja
MXPA04003215A (es)	2005-01-25	Derivados de triazapina como agentes neurotroficos.